To determine if healthcare-associated (HA)-respiratory syncytial virus (RSV) is associated with worse outcomes, this multicenter cohort study studied 26 children with HA-RSV and 78 matched non-HA-RSV patients of whom 58% and 55%, respectively, had ≥2 comorbidities. Overall, 39% of HA-RSV versus 18% of non-HA-RSV patients required respiratory support escalation (adjusted odds ratio (aOR) 5.1, CI95 1.4, 19.1).
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11599150 | PMC |
http://dx.doi.org/10.1093/jpids/piae099 | DOI Listing |
Clin Immunol
December 2024
Department of Microbiology, Gachon University College of Medicine, Incheon, Republic of Korea; Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Republic of Korea; Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon, Republic of Korea; Korea mRNA Vaccine Initiative, Gachon University, Seongnam, Republic of Korea. Electronic address:
Over the last decade, mRNA vaccines development has shown significant advancement, particularly during the COVID-19 pandemic. This comprehensive review examines the efficacy of pivotal vaccines against emerging COVID-19 variants and strategies for enhancing vaccine effectiveness. It also explores the versatility of mRNA technology in addressing other infectious diseases such as influenza, respiratory syncytial virus, HIV, cytomegalovirus, Ebola, Zika, Rabies, and Nipah viruses.
View Article and Find Full Text PDFVaccine
December 2024
School of Population Health, Faculty of Medicine and Health, UNSW Sydney, New South Wales, Australia.
Background: Respiratory syncytial virus (RSV) is a major cause of respiratory illness, with younger infants at greatest risk of hospitalisation. With the recent approval of a maternal RSV vaccine in Australia, it is timely to evaluate its potential costs and health benefits in Australia.
Methods: We applied an integrated dynamic and economic evaluation model to estimate specific outcomes of RSV disease and the cost-effectiveness of a year-round maternal RSV vaccination program in Australia.
Pediatr Infect Dis J
October 2024
From the Department of Paediatrics and Child Health, Faculty of Health Sciences, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa.
Background: No data are available regarding the interplay and clinical manifestations of respiratory syncytial virus (RSV) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) coinfection in African children. We compared clinical characteristics and outcomes between RSV-only, SARS-CoV-2-only and RSV/SARS-CoV-2 coinfection lower respiratory tract infections (LRTI) in hospitalized African children.
Methods: Prospective surveillance of children (0-59 months) hospitalized with severe LRTI was undertaken between March 1, 2020, and March 31, 2023, in Johannesburg, South Africa.
Arch Bronconeumol
December 2024
Servicio de Pediatría, Hospital Infantil Gregorio Marañón, Spain; Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid, Spain.
Clin Microbiol Infect
December 2024
National Centre for Infectious Diseases, Singapore; Duke-NUS Graduate Medical School, National University of Singapore, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Ministry of Health, Singapore; Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
Objectives: Most studies on long-term sequelae of SARS-CoV-2-infection in children were conducted pre-Omicron and pre-dated vaccination rollout. We examined long-term risk of new-incident multi-systemic sequelae after SARS-CoV-2 Delta/Omicron infection in a multi-ethnic Asian pediatric population.
Methods: Retrospective cohort study of Singaporean children aged 1- 17 years infected during Delta/Omicron BA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!